Clinical characteristics of patients with SLE under dialysis over time.
| 1995-2000 | 2000-2010 | 2010-2020 | P (Trend Over Time) | ||||
|---|---|---|---|---|---|---|---|
| PD | HD | PD | HD | PD | HD | ||
| Patients | 2 (40) | 3 (60) | 11 (28) | 27 (71) | 12 (15) | 66 (84) | 0.90 |
| Age, yrs, median (IQR) | 37 (32-42) | 44 (42-52) | 35 (30-37) | 34 (31-49) | 36 (30-48) | 43 (31-53) | 0.31 |
| Female sex | 2 (100) | 3 (100) | 9 | 20 | 18 | 51 | 0.48 |
| BMI, kg/m2, mean (SD) | 17.5 (1.6) | 19.3 (1.2) | 21.9 (4.7) | 20.9 (2.9) | 22.0 (3.6) | 21.9 (3.8) | 0.10 |
| SLE disease duration, months | 20 (11-29) | 4.8 (4-5.56) | 88 (60-101) | 72 (40-110) | 95 (3-123) | 113 (34-188) | 0.01 |
| Disease duration, LN onset to ESRD, months | 19 (10-27) | 4.8 (4-5.5) | 88 (60-100) | 63 (22-98) | 70 (2-100) | 89 (27-160) | 0.03 |
| Patients with disease flare during additional follow-up | 2 (100) | 0 (0) | 4 (36) | 7 (25) | 6 (50) | 16 (24) | 0.72 |
| Medicationsa | |||||||
| Hydroxychloroquine | 0 (0) | 0 (0) | 1 (9) | 3 (11) | 2 (16) | 17 (25) | 0.63 |
| Corticosteroids | 2 (100) | 2 (66) | 4 (36) | 19 (70) | 3 (25) | 49 (74) | 0.12 |
| Mycophenolate mofetil | 0 (0) | 0 (0) | 2 (18) | 5 (18) | 2 (16) | 19 (28) | 0.13 |
| Tacrolimus | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 2 (16) | 21 (31) | 0.76 |
| Cyclophosphamide | 1 (50) | 1 (33) | 2 (18) | 5 (18) | 1 (8) | 12 (18) | 0.22 |
| Azathioprine | 1 (50) | 0 (0) | 1 (9) | 3 (11) | 0 (0) | 4 (6) | 0.98 |
| Rituximab | 0 (0) | 0 (0) | 0 (0) | 1 (3) | 0 (0) | 3 (4) | 0.68 |
Values are expressed as n (%) unless indicated otherwise. Values in bold are statistically significant.
↵a Medications taken 1 year prior to the initiation of dialysis. ESRD: endstage renal disease; HD: hemodialysis; LN: lupus nephritis; PD: peritoneal dialysis; SLE: systemic lupus erythematosus.